Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
2023年11月7日 - 10:05PM
Ceapro Inc. (TSX-V: CZO; OTCQX:
CRPOF) (“Ceapro” or the “Company”), a growth-stage
biotechnology company focused on the development and
commercialization of active ingredients and disruptive technologies
for healthcare and cosmetic industries, announced today the signing
of a technical collaboration with Austria-based NATEX
Prozesstechnologie GmbH to accelerate the scale-up of its
proprietary PGX Technology towards commercial level. The
combination of Ceapro’s natural ingredient processing expertise
along with NATEX’ deep knowledge of commercial high-pressure
extraction equipment is providing a clear path to sustainable,
large-scale production of PGX materials.
The signing of this agreement results from
Ceapro’s ongoing efforts to reduce time to market for PGX-processed
materials. The sequential scale up path originally announced (from
10L to 50L and then 100L) has been revised to take place
concurrently. Ceapro’s ability to finalize specifications and test
methods for high purity YBG has enabled PGX plant design to move
forward with substantially fewer variables and less risk.
Leveraging the fully defined YBG standard, a 50L plant is being
installed and tested at Ceapro’s existing facility in Edmonton
instead of the University of Alberta. Pilot production at Ceapro’s
Edmonton facility is also taking advantage of the existing
manufacturing site license for natural health products. Space at
the University is being retained for other upcoming opportunities
under discussion.
All ongoing advancements, along with NATEX’
capability as a global leader in design, construction, and
commissioning of high-pressure supercritical CO2 processing plants,
is enabling the design and construction of the 100L plant in
parallel with the 50L plant. 100L design and construction are
underway at NATEX pilot testing facilities in Austria. The Austrian
facility was selected since many components are already in place
for supporting the PGX process. Furthermore, equipment purchased by
Ceapro from a German facility prior to the pandemic has also been
refurbished and is ready to be integrated into the 100L plant in
Austria. NATEX are experts at design and construction of full-scale
commercial plants based on the 100L scale. Successful results from
these projects are to pave the way for commercialization of YBG as
an immune booster and as a basis for the construction of a large
commercial scale unit in Canada.
As mentioned in the press release on August 29,
2023, the 50L plant should be installed by year-end and
commissioned during the first quarter of 2024 while the 100L should
be completed during the third quarter of 2024.
PGX has the potential to transform drug and
bioactive delivery and, ultimately, enable the creation of
first-in-class nutraceutical and pharmaceutical products. This
presents many business growth opportunities for both Ceapro and
NATEX as the deployment of several commercial plants is envisioned
with each new product.
“The Ceapro team is dedicated to following a
focused timeline for scaling up PGX to a point where commercial
plants can be fully defined in terms of engineering, construction
costs and timelines. This collaboration with NATEX has added
the needed experience, expertise, and resources to bring these
projects to fruition as quickly as possible,” said Michel Regnier,
P. Eng., Senior Vice-President, Technical Operations at Ceapro.
“Collaboration with Ceapro on the PGX project is
very much in line with our expertise and our mission to introduce
new industrial supercritical fluid technologies for innovative
products and processes for future society. Completion of the 100L
scale-up in our Process and Product Development Center brings
everything close at hand, gives us the opportunity to ensure the
robustness for scale-up and keeps timelines as short as possible.
We estimate that we already have 50% of the required infrastructure
and equipment to secure this project,” added Ing. Franz Seitinger
M.A., Managing Director at NATEX.
“We are very pleased with this revised plan for
the PGX Technology which is key to the Company’s future given its
potential for the creation of first-in-class nutraceuticals and
pharmaceuticals under various formulations. The signing of
partnerships for further development and commercialization of
PGX-processed innovative products are directly related to the
timely development of this technology at large scale. We look
forward to a win-win completion of this project along with the
NATEX experts,” concluded Mr. Gilles Gagnon, M.Sc., MBA, President
and CEO.
About Pressurized Gas eXpanded Liquid
Technology (PGX) Ceapro’s patented Pressurized Gas
eXpanded (PGX) Technology is a unique and disruptive supercritical
fluid technology with several key advantages over conventional
drying and purification technologies that can be used to process
biopolymers into high-value, fine-structured, open-porous polymer
structures and novel biocomposites. PGX Technology is ideally
suited for processing challenging high-molecular-weight,
water-soluble biopolymers. It has the ability to make ultra-light,
highly porous polymer structures on a continuous basis, which is
not possible using today's conventional technologies. PGX
Technology was invented by Dr. Feral Temelli from the Department of
Agricultural, Food & Nutritional Science of the University of
Alberta (U of A) along with Dr. Bernhard Seifried, now Senior
Director of Research and Technology at Ceapro. The license from U
of A provides Ceapro with exclusive worldwide rights in all
industrial applications.
About NATEX Prozesstechnologie
GesmbHHigh pressure CO2 technology has several
technical and environmental advantages, and the products have
health benefits compared to conventional organic solvent processes.
NATEX believes these advantages should be utilized in as many
industrial applications as possible. Since 1993, NATEX has focused
all resources and know-how on the development and research of
Supercritical Fluid Extraction Technology. Key industrial scale
projects for new applications include the first industrial CO2
decaffeination plant with continuous recovery of caffeine, the
first rice extraction plant and the first industrial cork cleaning
plant, among others. NATEX is also the global leader in scaling up
existing processes which has been proven by the worlds biggest
pharmaceutical extraction plant, the worlds biggest hops extraction
plant and the industrialization of wood impregnation. For more
information, visit www.natex.at
About Ceapro Inc. Ceapro
Inc. is a Canadian biotechnology company involved in the
development of proprietary extraction technology and the
application of this technology to the production of extracts and
“active ingredients” from oats and other renewable plant resources.
Ceapro adds further value to its extracts by supporting their use
in cosmeceutical, nutraceutical, and therapeutics products for
humans and animals. The Company has a broad range of expertise in
natural product chemistry, microbiology, biochemistry, immunology
and process engineering. These skills merge in the fields of active
ingredients, biopharmaceuticals and drug-delivery solutions. For
more information on Ceapro, please visit the Company’s website at
www.ceapro.com.
For more information contact: Jenene
Thomas JTC Team, LLC Investor Relations and Corporate
Communications Advisor T (US): +1 (833) 475-8247 E:
czo@jtcir.com
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release
Ceapro (TSXV:CZO)
過去 株価チャート
から 4 2024 まで 5 2024
Ceapro (TSXV:CZO)
過去 株価チャート
から 5 2023 まで 5 2024